Back to top
more

Intellia Therapeutics (NTLA)

(Delayed Data from NSDQ)

$11.58 USD

11.58
3,451,899

-0.54 (-4.46%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $11.53 -0.05 (-0.43%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks News

Zacks Equity Research

Intellia's (NTLA) NTLA-5001 Gets FDA Orphan Drug Tag for AML

Intellia's (NTLA) investigational gene-editing therapy, NTLA-5001, gets an Orphan Drug tag from the FDA for AML.

Zacks Equity Research

Intellia (NTLA) Q4 Loss Wider Than Expected, Revenues Up Y/Y

Intellia Therapeutics (NTLA) reports wider-than-expected Q4 loss. Nonetheless, revenues beat estimates.

Zacks Equity Research

Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates

Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of -19.78% and 33.35%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Should iShares Russell 2000 Growth ETF (IWO) Be on Your Investing Radar?

Style Box ETF report for IWO

Zacks Equity Research

Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q4 Earnings Expected to Decline

Intellia Therapeutics, Inc. (NTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Intellia (NTLA) Up on Deal With ONK for Cancer Therapies

Intellia (NTLA) partners with ONK Therapeutics. The collaboration utilises their respective proprietary platforms to develop allogeneic CRISPR-based NK cell therapies for the treatment of cancer.

Zacks Equity Research

Should Vanguard Russell 2000 Growth ETF (VTWG) Be on Your Investing Radar?

Style Box ETF report for VTWG

Zacks Equity Research

Editas (EDIT) Focuses on Developing Gene-Editing Eye Drug

Editas' (EDIT) lead pipeline candidate, EDIT-101, which employs CRISPR gene editing to treat LCA10, holds potential. Dependence on partners for collaboration revenues a woe.

Zacks Equity Research

Intellia (NTLA) Inks Deal With Kyverna for Autoimmune Diseases

Intellia (NTLA) inks a licensing and collaboration deal with Kyverna Therapeutics for developing an allogeneic CAR T-cell therapy for autoimmune diseases.

Zacks Equity Research

Intellia's (NTLA) CRISPR Therapies Show Promise Amid Competition

While Intellia's (NTLA) pipeline is in early-stage clinical studies, its development is progressing well. Collaborations are a primary source of revenues in the absence of a marketed product.

Ekta Bagri headshot

5 Biotech Stocks That More Than Doubled This Year

The biotech sector has been in focus through 2021 as vaccine makers like Moderna (MRNA) BioNTech (BNTX), and other companies like Dynavax (DVAX), Prothena (PRTA) and Intellia (NTLA) put up an exemplary performance.

Zacks Equity Research

Should iShares Russell 2000 Growth ETF (IWO) Be on Your Investing Radar?

Style Box ETF report for IWO

Zacks Equity Research

Should Vanguard Russell 2000 Growth ETF (VTWG) Be on Your Investing Radar?

Style Box ETF report for VTWG

Zacks Equity Research

Intellia (NTLA) Begins Dosing in Hereditary Angioedema Study

Intellia (NTLA) doses the first patient in a phase I/II study to evaluate NTLA-2002 as a single-dose therapy for preventing attacks in patients having hereditary angioedema.

Zacks Equity Research

Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Lags Revenue Estimates

Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of -14.12% and -16.24%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

Smart Beta ETF report for XBI

Zacks Equity Research

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

Sector ETF report for XBI

Zacks Equity Research

Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q3 Earnings Expected to Decline

Intellia Therapeutics, Inc. (NTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Intellia's (NTLA) CRISPR Therapy Gets FDA's Orphan Drug Tag

Intellia's (NTLA) investigational gene-editing therapy, NTLA-2001, gets Orphan Drug tag from the FDA for ATTR amyloidosis.

Zacks Equity Research

Should iShares Russell 2000 Growth ETF (IWO) Be on Your Investing Radar?

Style Box ETF report for IWO

Zacks Equity Research

Editas (EDIT) Focuses on Developing Gene Drug for Eye Disease

Editas (EDIT) progresses well with the development of its lead candidate, EDIT-101, to treat LCA10, a rare genetic illness that causes blindness. Dependence on partners for revenues is a concern.

Zacks Equity Research

Editas (EDIT) Down on Initial Data From Eye Disease Study

Editas (EDIT) posts initial data from the phase I/II BRILLIANCE study evaluating EDIT-101 for treating Leber congenital amaurosis 10, an inherited form of blindness.

Zacks Equity Research

New Strong Sell Stocks for August 24th

BGS, FTHM, NTLA, LEVL, and ELOX have been added to the Zacks Rank #5 (Strong Sell) List on August 24, 2021

Zacks Equity Research

Editas (EDIT) Up More Than 70% in Past 3 Months: Here's Why

Editas' (EDIT) lead candidate, EDIT-101, which employs CRISPR gene editing to treat LCA10, holds potential. The company is also developing EDIT-301 for treating hematologic diseases.

Sweta Jaiswal, FRM headshot

How Are Genomics ETFs Responding to Q2 Earnings?

Let's take a look at some big genomics earnings releases to see if these will impact ETFs exposed to the space.